Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1 5Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Mesothelioma, Malignant 1

Interventions

Cisplatin 726Carboplatin 609Paclitaxel 579Cyclophosphamide 516Radiotherapy 511Docetaxel 477Fluorouracil 454Gemcitabine 438Doxorubicin 383Capecitabine 361Dexamethasone 328Oxaliplatin 289pembrolizumab 283Leucovorin 283Bevacizumab 275Etoposide 272Vincristine 270Rituximab 246Prednisone 223Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 176Irinotecan 174Methotrexate 171Lenalidomide 137Nivolumab 136Filgrastim 135Epirubicin 129Tamoxifen 128

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × tumor necrosis factor-alpha, CNGRC fusion protein, human × Clear all
NCT01098266 2019-09-17

NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

AGC Biologics S.p.A.

Phase 3 Completed
400 enrolled 16 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡